IO 160
Alternative Names: CALRLong36 exon 9 mutant peptide vaccine - IO Biotech; Exon 9 mutated peptide + Montanide ISA-51 - IO Biotech; IO-160Latest Information Update: 28 Jul 2021
At a glance
- Originator Herlev Hospital; IO Biotech
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myeloproliferative disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Myeloproliferative disorders in Denmark (Parenteral)